Broncasma Berna aerosol therapy for chronic sinusitis

A multi-center joint dose-comparative study

Abstract

Outpatients with chronic sinusitis were divided into 3 groups by the envelope method, and 1ml of 2-fold, 4-fold, and 20-fold dilutions of Broncasma Berna were administered into the nasal cavity using a jet type nebulizer twice a week for 4-8 weeks. The efficacy and safety of the aerosol therapy were compared according to the dose.
1. Concerning the subjective symptoms, rhinorrhea improved significantly in all groups. Marked or moderate improvements were observed in 33% of the 2-fold dilution group, 64% of the 4-fold dilution group, and 31% of the 20-fold dilution group.
2. Conceming the objective symptoms, improvements were observed in the volume of nasal secretion in the 20-fold dilution group and the quality of nasal secretion in the 4-fold dilution group. Marked or moderated improvements were observed in 17, 36, and 15% of the 2-fold, 4-fold, and 20-fold dilution groups, respectively.
3. The treatment was considered to be either very useful or moderately useful in 33% of the 2-fold dilution group, 46% of the 4-fold dilution group, and 15% of the 20-fold dilution group, while it was found to be at least slightly useful in 75%, 91%, and 77%, respectively.